EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against ESSA Pharma Inc. for alleged violations of securities laws, specifically related to misleading statements about the efficacy of its drug masofaniten in combination with enzalutamide [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that ESSA made false and misleading statements regarding the effectiveness of masofaniten when used with enzalutamide for treating prostate cancer [4]. - The class period for the lawsuit is defined as December 12, 2023, to October 31, 2024, during which investors are encouraged to participate if they suffered losses [2]. Group 2: Investor Information - Investors who purchased ESSA's securities during the class period are urged to contact the Schall Law Firm before March 25, 2025, to discuss their rights [2][3]. - The class has not yet been certified, meaning that until certification occurs, affected investors are not represented by an attorney [3].